Andrés David Aranzazu Ceballos, Lina María Martínez Sánchez, Ana Paulina Pamplona Sierra, Daniela Vergara Yánez, Liliana Franco Hincapié, Richard Baquero Rodriguez
{"title":"Primary Thrombotic Microangiopathy in Pediatric Patients.","authors":"Andrés David Aranzazu Ceballos, Lina María Martínez Sánchez, Ana Paulina Pamplona Sierra, Daniela Vergara Yánez, Liliana Franco Hincapié, Richard Baquero Rodriguez","doi":"10.1177/2333794X241307535","DOIUrl":null,"url":null,"abstract":"<p><p><i>Background</i>. Primary thrombotic microangiopathy includes hemolytic uremic syndrome caused by Shiga toxin-producing <i>Escherichia coli</i>, atypical hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura. <i>Methodology</i>. A retrospective study that included patients younger than 18 years diagnosed with primary thrombotic microangiopathy between 2011 and 2021. <i>Results</i>. Thirty patients were included, of which 63% corresponded to a hemolytic uremic syndrome caused by Shiga toxin-producing <i>Escherichia coli</i>, and 30% to the atypical hemolytic uremic syndrome. The median age was 2.8 years and female sex predominated at 57%. On admission to the emergency room, fever and fatigue were the most frequent symptoms (93%), followed by oliguria and anuria (80%). 48% of patients received hemodialysis during their care. Mortality was estimated at 13%. <i>Conclusion</i>. This study constitutes the largest series of primary thrombotic microangiopathy in the pediatric population of Latin America, where the etiological and clinical behavior of this condition is described.</p>","PeriodicalId":12576,"journal":{"name":"Global Pediatric Health","volume":"11 ","pages":"2333794X241307535"},"PeriodicalIF":1.4000,"publicationDate":"2024-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11650636/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Global Pediatric Health","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/2333794X241307535","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"PEDIATRICS","Score":null,"Total":0}
引用次数: 0
Abstract
Background. Primary thrombotic microangiopathy includes hemolytic uremic syndrome caused by Shiga toxin-producing Escherichia coli, atypical hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura. Methodology. A retrospective study that included patients younger than 18 years diagnosed with primary thrombotic microangiopathy between 2011 and 2021. Results. Thirty patients were included, of which 63% corresponded to a hemolytic uremic syndrome caused by Shiga toxin-producing Escherichia coli, and 30% to the atypical hemolytic uremic syndrome. The median age was 2.8 years and female sex predominated at 57%. On admission to the emergency room, fever and fatigue were the most frequent symptoms (93%), followed by oliguria and anuria (80%). 48% of patients received hemodialysis during their care. Mortality was estimated at 13%. Conclusion. This study constitutes the largest series of primary thrombotic microangiopathy in the pediatric population of Latin America, where the etiological and clinical behavior of this condition is described.